Abivax (NASDAQ:ABVX – Get Free Report) and SELLAS Life Sciences Group (NASDAQ:SLS – Get Free Report) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, analyst recommendations, valuation and institutional ownership.
Analyst Recommendations
This is a summary of recent ratings and price targets for Abivax and SELLAS Life Sciences Group, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Abivax | 1 | 1 | 14 | 0 | 2.81 |
| SELLAS Life Sciences Group | 1 | 0 | 2 | 0 | 2.33 |
Abivax presently has a consensus price target of $148.54, indicating a potential upside of 12.96%. SELLAS Life Sciences Group has a consensus price target of $10.00, indicating a potential downside of 19.87%. Given Abivax’s stronger consensus rating and higher possible upside, research analysts clearly believe Abivax is more favorable than SELLAS Life Sciences Group.
Earnings & Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Abivax | N/A | N/A | -$380.27 million | ($5.21) | -25.24 |
| SELLAS Life Sciences Group | N/A | N/A | -$26.86 million | ($0.23) | -54.26 |
SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than Abivax, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
47.9% of Abivax shares are owned by institutional investors. Comparatively, 17.4% of SELLAS Life Sciences Group shares are owned by institutional investors. 1.3% of SELLAS Life Sciences Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Profitability
This table compares Abivax and SELLAS Life Sciences Group’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Abivax | N/A | -99.02% | -70.26% |
| SELLAS Life Sciences Group | N/A | -47.12% | -42.63% |
Volatility and Risk
Abivax has a beta of 0.87, indicating that its stock price is 13% less volatile than the S&P 500. Comparatively, SELLAS Life Sciences Group has a beta of 2.42, indicating that its stock price is 142% more volatile than the S&P 500.
Summary
SELLAS Life Sciences Group beats Abivax on 6 of the 11 factors compared between the two stocks.
About Abivax
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.
About SELLAS Life Sciences Group
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company’s lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
Receive News & Ratings for Abivax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abivax and related companies with MarketBeat.com's FREE daily email newsletter.
